Papers And Originals

Treatment of Acute Myeloblastic Leukaemia with RP 22050

Br Med J 1972; 4 doi: https://doi.org/10.1136/bmj.4.5838.468 (Published 25 November 1972) Cite this as: Br Med J 1972;4:468
  1. C. Jacquillat,
  2. M. Weil,
  3. M. F. Gemon,
  4. V. Izrael,
  5. G. Schaison,
  6. M. Boiron,
  7. Jean Bernard

    Abstract

    Fourty-four patients with acute myeloblastic leukaemia were treated with RP 22050, a new, semisynthetic derivative of daunorubicin. Complete remissions were achieved in 20 patients (45%). The median dose given was 23 mg/kg. The toxicity of RP 22050 is mainly haematological. Resistance rather than death in aplasia seemed to be the cause of failure of therapy.